Current clinical management of metastatic lung cancer

摘要: Approximately 40% of patients with non-small cell lung cancer (NSCLC) and 70% small (SCLC) present advanced, hematogenously metastatic, incurable disease. Systemic chemotherapy is the mainstay therapy in these primary goals palliating symptoms, maintaining quality life, prolonging life. For advanced NSCLC, standard treatment consists two-drug, platinum-based or without bevacizumab, a monoclonal antibody targeting vascular endothelial growth factor which controls tumor angiogenesis. In second- third-line epidermal receptor inhibitors has also been shown to provide survival benefit. Recent studies have begun define specific clinical, histological, molecular characteristics that can help identify subsets NSCLC who will not respond particular chemotherapeutic molecularly targeted agents. extensive-stage SCLC, initial yields impressive response rates, but long-term remains extremely limited. Despite extensive knowledge biology therapies yet demonstrate any significant clinical benefits this